Introduction {#S1}
============

Understanding the significance and varied uses of terms that describe cardiac function requires familiarity with the methods and limitations inherent in conducting *in vitro* and *in vivo* muscle experiments and their translation to clinical practice ([@B46]; [@B111]; [@B112]; [@B79]; [@B78]; [@B92]; [@B107]; [@B119]; [@B128]; [@B69]; [@B86]; [@B129]; [@B130]). Muscle contraction enables animals to move and hollow organs with one-way valves, like the heart, to generate force and transfer blood from veins to arteries. The properties of the heart that permit its function are described in terms possessing the suffix "tropic" (i.e., affecting or influenced by): chronotropic, bathmotropic, dromotropic, inotropic, lusitropic, and occasionally clinotropic ([Figure 1](#F1){ref-type="fig"}; [@B119]; [@B73]; [@B130]). Of these, the adjective inotropic (i.e., affecting force) or abstract noun inotropy stand out as the primary focus of more than 15,000 PubMed citations (PubMed/MEDLINE, Cochrane Library, Web of Science, [ClinicalTrials.gov](https://clinicaltrials.gov)) that have investigated the effects of various diseases, chemical compounds, devices or toxins on the ability of the heart to develop force (positive or negative inotropes) or to improve force development in patients with various types of heart failure (HF) ([@B8]; [@B33]; [@B114]; [@B148]).

![Terms used to describe the properties of cardiac cells include: chronotropy, bathmotropy, dromotropy, lusitropy, inotropy, and clinotropy. Left: Cardiac muscle fibers are comprised of repeating units of sarcomeres that are separated by *Z*-disks and contain the contractile proteins actin (thin filament) and myosin (thick filament). Center: Increases in cardiac contractility are usually represented by directionally similar changes in both force and velocity. Right: A power curve is generated as the product of force and velocity at each point along the F-V curve. V = Velocity; V~*max*~ = maximal velocity at no load; F = Force; P = power; W = work; l = length; t = time; Δ = change; M-Line = attachment site for the thick filaments and center of the sarcomere; *Z*-Disk = the anchoring point for thin filaments that separate sarcomeres.](fphys-11-00222-g001){#F1}

Of particular relevance to the current discussion is the identification and investigation of genetic mutations and compounds that change the heart's inotropic state by altering sarcomeric protein cross-bridge (XB) kinetics ([@B120], [@B121]; [@B3]; [@B133]; [@B132]; [@B83]; [@B143]). The small molecule myosin regulator, omecamtiv mecarbil, for example, enhances sarcomeric force development by increasing the number and synchrony of strongly bound myosin crossbridges (XB's), thereby increasing sarcomeric force independent of changes in intracellular calcium concentration \[Ca^+2^\]~*i*~, calcium transients, shortening velocity or oxygen consumption ([@B70]; [@B133]; [@B141]; [@B44]; [@B97]; [@B131]; [@B53]; [@B122]; [@B62]). Alternatively, compounds that reduce sarcomeric force without changing shortening velocity or the rate of myocardial relaxation (ex. para-nitroblebbistatin; mavacapten) are being studied as treatment for hypertrophic cardiomyopathy (HCM) ([@B58]; [@B132]; [@B52]; [@B122]).

Enter the ubiquitous term "contractility," a term freely applied to describe the heart's performance, or used as a synonym for inotropy. This conflation of terms creates misunderstandings and more importantly confuses descriptions of experimental results and test article effects.

Jewell summarized "the essence" of how muscle length regulates contraction more than 40 years ago by stating: "The end result of excitation-contraction coupling is the formation of tension-generating cross-bridges between overlapping parts of the thick (myosin) and thin (actin) filaments that make up the contractile system" ([@B51]). Subsequent research has provided excellent descriptions of cardiac muscle cell electrophysiology, \[Ca^+2^\]~*i*~ cycling (calcium induced- calcium release) and the sequence of processes responsible for cardiac muscle contraction (excitation-contraction coupling) ([@B11]; [@B48]; [@B22]; [@B107]; [@B29]; [@B129]). Current investigations of cardiac muscle contraction are focused on the biochemistry (i.e., chemo-mechanical cycle), mechano-sensing and kinetic behavior of sarcomeric proteins since it is generally believed that cardiac muscle contraction: "has its roots in the individual molecular motors working in every muscle cell -- the myosin molecule" ([@B46]; [@B48], [@B50]; [@B106]; [@B123]; [@B120]; [@B128]; [@B68]; [@B71]). This perspective provides historical and contemporary evidence for conveying definitions of the terms cardiac performance, inotropy and contractility.

Cardiac Function: Definitions of Cardiac Performance, Inotropy and Contractility {#S2}
================================================================================

Cardiac Performance {#S2.SS1}
-------------------

Cardiac performance is the ability of the heart to pump blood into arteries and is expressed as cardiac output per unit time or as stroke volume per heartbeat. Factors that modulate the heart's ability to pump blood (i.e., perform) include heart rate ([@B16]; [@B20]), loading conditions (i.e., preload, afterload) ([@B80]; [@B89]; [@B113]; [@B77]; [@B144]; [@B91]), the myosin molecules contractile state ([@B120]), ventricular geometry ([@B67]), elastance (i.e., stiffness) ([@B34]; [@B36]; [@B127]; [@B103]; [@B126]; [@B93]; [@B149]; [@B19]; [@B142]; [@B60]), ventricular-vascular coupling ([@B54]; [@B7]; [@B142]) and prevailing neurohumoral activity, especially sympathetic-parasympathetic tone ([@B137]; [@B39]). Changes in preload and afterload have been described as "preload reserve" and "afterload matching," respectively ([@B17]; [@B99]; [@B101]; [@B142]; [@B105]; [@B13]). Key determinants of pump performance include heart rate, preload (volume of blood within a chamber), afterload (hindrance to ejection), and contractility. Pump performance may decrease (e.g., decrease in heart rate or preload; increase in afterload) or increase (e.g., increase in heart rate or preload; decrease in afterload) dependent upon changes in loading conditions but independent of contractility. Cardiac performance should be operationally defined as the heart's ability to pump blood \[ex. cardiac output (CO)\].

Inotropy {#S2.SS2}
--------

The term "inotropic" is formed from the Greek word *ino* (sinew) and the suffix "*tropic*." It is commonly employed in physiology to mean the force of muscular contraction. This usage most likely evolved from the Germanic translation of the term sinew to mean vigor, strength, or power. The terms inotropy, inotropism, inotropic, and inotrope have all been applied to describe the force or tension developed during muscle contraction. Most physiologists agree that the force generated by a contracting isolated muscle is dependent upon sarcomere length, \[Ca^+2^\]~*i*~, the velocity of sarcomere shortening when shortening against zero load, the type of myosin (α vs. β), and the state of phosphorylation of myosin ([@B116]; [@B25]; [@B135]; [@B66]; [@B27]; [@B134]; [@B41]). Experimentally derived length-force, length-velocity, force-velocity, and length-force-velocity relationships obtained from isolated (*in vitro*) cardiac muscle fiber experiments have inextricably linked force with velocity ([@B116], [@B117]; [@B87]; [@B118]; [@B47]; [@B42]; [@B147]; [@B135]; [@B27]).

Inotropy is muscle fiber length dependent and is modified by heterometric autoregulation \[Cyon-Frank-Starling mechanism ([@B150], [@B151]; [@B57]; [@B4]; [@B108])\], homeometric autoregulation \[von Anrep effect *in vivo*; slow force response *in vitro* ([@B104]; [@B23]; [@B24]; [@B35]; [@B105])\], the force-frequency relationship \[Bowditch, treppe, staircase effect, chronotropic-inotropy ([@B14]; [@B88]; [@B5]; [@B45]; [@B43]; [@B100]; [@B30]; [@B49]; [@B48]; [@B98])\], and autonomic activity ([@B38]; [@B136]; [@B100]). Inotropy decreases almost instantly, within one heartbeat, when parasympathetic activity increases, and more slowly, over 6--8 s, when sympathetic efferent activity changes ([@B90]). The term inotropy and its derivatives should be operationally defined as force.

Contractility {#S2.SS3}
-------------

The term "contractility" is historically embedded in both the experimental and clinical cardiovascular literature and is formed from the adjective *contractile* and the suffix "*ility*" (i.e., quality), thereby forming the abstract noun contractility. The word contractile (derived from French: 1706) implies that something has the ability to shrink or shorten. Striated muscle cells and sarcomeres shrink because the contractile proteins (i.e., actin, myosin) slide past one another, developing a force that pulls the sarcomeric Z-bands closer together. The proximate source of contraction, however, arises from the cycling of actomyosin XBs that apply force to actin filaments ([@B107]: [@B130]).

One editor in chief of a highly respected research journal has stated that, "the term contractility remains useful in order to permit succinct written and oral communication between and among scientists and clinicians" ([@B115]). Others are not convinced and consider the term to be "hotly debated" ([@B129]) and "ill-defined."^[1](#footnote1){ref-type="fn"}^ Many authors equate the term with inotropy ([@B5]; [@B85]; [@B115]; [@B119]). One noted cardiovascular scholar went so far as to state, "If it weren't for pressure-volume (P-V) loops and the end systolic pressure volume relationship (ESPVR), the term contractility would likely have disappeared" ([@B81]). The same author went on to state, "In view of the vagueness of the definitions, it may be worthwhile in the future to eliminate this term (i.e., contractility) entirely from the literature" ([@B81]). Shepherd and Vanhoutte proposed that cardiac contractility be defined as, "the intensity of the active state" that is evoked, "by the interaction between the actin and myosin molecules as a consequence of the integration of the biochemical and biophysical events resulting in the actomyosin interaction described only by a complex relationship between the force exerted by the muscle, the velocity of shortening, its length and the time of the contractile cycle at which these parameters are measured" ([@B109]). Other noted muscle physiologists and clinical cardiologists have provided more detailed definitions by asserting that contractility implies the intrinsic ability of the heart, at a fixed heart rate, to generate force and shorten independent of preload and afterload ([@B85]; [@B125]; [@B18]; [@B2]; [@B12]). A focused group of molecular physiologists stated that, "Cardiac contractility can be defined as the tension developed and velocity of shortening (i.e., the "strength" of contraction) of myocardial fibers at a given preload and afterload. It represents a unique and intrinsic ability of cardiac muscle (contracting at a fixed heart rate) to generate a force that is independent of any load or stretch applied" ([@B146]). Integral to all current definitions of the term contractility is the tacit requirement that it is independent of loading conditions ([@B15]; [@B26]; [@B56]; [@B55]; [@B95]; [@B12]; [@B105]) (See footenote 1).

Much of what is known about the contractile properties of the heart has been derived from *in vitro* experiments conducted on skeletal or cardiac muscle strips, fascicles, or fibers ([@B116]; [@B56]; [@B37]; [@B57]: [@B10]) obtained from various mammalian species ([@B1]; [@B51]; [@B107]; [@B28]; [@B129]) in solutions where the \[Ca^+2^\]~*i*~ was manipulated ([@B87]; [@B59]; [@B86]). Pairs of myosin heads encircle the thick myosin filament backbone in a helical or quasi-helical fashion and are described as existing in one of three transitional states: active, or when not active, disordered relaxed (DRX; approximately 50--60%) and super-relaxed (SRX: approximately 40--50%) ([@B76]; [@B6]). Only 10--30% of the total myosin S1 heads develop strong bonds and complete one or two XB cycles during the contractile period (low duty ratio) ([@B120]; [@B10]). Various mechanical properties have been deduced from stretched (i.e., preloaded) cardiac muscle fibers stimulated to contract against varying (i.e., isotonic) or an infinite (i.e., isometric) load (i.e., afterload) ([@B116]; [@B117]; [@B87]; [@B25]; [@B75]). Notably, the tissues visco-elastic properties permit the sarcomeres (i.e., contractile units) in each muscle fiber to shorten and develop force (i.e., tension) regardless of the imposed loading conditions, whether or not the muscle fiber shortens ([@B36]; [@B126]; [@B28]). The force-velocity relation extrapolated to zero load (i.e., V~*max*~) has long been considered a load independent and "complete" ([@B118]) measure of cardiac contractility, particularly in isolated muscle strips ([@B102]; [@B118]; [@B47]; [@B74]; [@B94]; [@B17]; [@B61]) so long as it is "reflected by maximum force development as well as the velocity of shortening" ([@B125]). These studies have determined that muscle shortening velocity is inversely related to force generation; an increase in muscle (i.e., sarcomere) length, at any given load, increases shortening velocity; force and velocity development are tightly correlated with ATP utilization and oxygen consumption; and the maximal velocity of sarcomere shortening is, in part, dependent upon myosin composition and the degree of synchrony among the less than 30% of XBs that cycle during each resting cardiac contraction ([@B9]; [@B40]; [@B25]; [@B110]; [@B28]).

Contemporary experimental studies of muscle contraction suggest that, "There is an apparent gap between basic and clinical science methods and measurements investigating cardiac contractile function, making it difficult to directly relate specific parameters of a XB cycle to the events in a cardiac cycle. But it is clear that ventricular contractile function is heavily dependent on XB kinetics" ([@B72]). Kinetic and cooperative load-dependent processes have determined that the myosin-actin attachment rate, overall cycle rate, the amount of time that myosin is attached to actin, and the total number of myosin heads in the active state (i.e., duty ratio) are all determinants of force (F) development, sliding velocity (V~*max*~) and the amount of ATP consumed ([@B123]; [@B131]; [@B68]; [@B130]; [@B50]). Harmonic force spectroscopy (HFS) experiments have provided further insights into how myosin's length-dependent kinetics (detachment: k~*det*~; recruitment: k~*rec*~) control XB transitions and are modified by biologic alterations that include small regulatory molecule conversions ([@B96]; [@B124]; [@B32]; [@B128]; [@B50]). Myosin head detachment rate (i.e., k~*det*~) has been identified as a key parameter influencing contractility because it determines the time myosin is bound to actin in a force producing state ([@B48]; [@B41]; [@B128]; [@B68]). The discovery of a host of cardiomyopathy mutations and a new generation of chemical compounds that modify myosin "motor" kinetics and chemo-mechanical processes ([@B70]; [@B121]; [@B133]; [@B84], [@B83]; [@B131]; [@B52]; [@B72]), which produce divergent effects on force and velocity suggest that revival of the term clinotropy (i.e., velocity) should be considered in order to more holistically define the term contractility as force (i.e., intoropy) and velocity (i.e., clinitropy) ([@B69]). Myocardial contractility should be defined as the load and length-independent, kinetically controlled, chemo-mechanical processes responsible for the development of force (inotropy) and velocity (clinotropy).

The Difference Between Cardiac Performance, Inotropy and Contractility in Normal and Diseased Hearts {#S3}
====================================================================================================

Cardiac contractility should not be confused or conflated with cardiac performance ([@B15]; [@B101]; [@B107]). The primary functions of the ventricles are to pump blood (vis a tergo) and to draw blood (vis a fronte) from the atria ([@B22]; [@B65]; [@B143]). The ability of the heart to perform this task (i.e., create blood flow) is dependent upon heart rate and loading conditions (i.e., preload, afterload) and by how well and at what cost (i.e., O~2~ consumption) the left and right ventricles (LV and RV, respectively) produce pressure gradients.

Cardiac pump performance can deteriorate, improve or remain the same when cardiac contractility is normal or abnormal, depending upon the magnitude of changes in heart rate and loading conditions (i.e., preload; afterload) ([@B145]; [@B99]; [@B101]). This conclusion is highlighted by clinical scenarios wherein the heart's pumping performance is enhanced by compensatory mechanisms (e.g., increased heart rate or preload, neuro-humeral activation) or drugs (e.g., antiarrhythmics, vasodilators), which improve cardiac output when cardiac contractility is decreased, or conversely, decrease cardiac output (i.e., increased afterload, blood loss, valvular stenosis or incompetence) when cardiac contractility is normal or enhanced ([@B139]; [@B31]; [@B138]). For example, aortic or mitral valve insufficiency can reduce cardiac output when cardiac contractility is increased ([@B21]; [@B101]; [@B63]).

Myocardial contractility is not only the ability of the heart to develop force (i.e., inotropy) but also the ability to generate velocity ([@B116], [@B117]; [@B118]; [@B74]; [@B28]; [@B68]; [@B50]). Genetic mutations and drugs that alter the cardiac actin-activated chemo-mechanical ATPase cycle and XB kinetics (i.e., k~*det*~) may cause force and velocity to change independently ([@B6]; [@B68]; [@B83]).

Conclusion {#S4}
==========

Cardiac muscle contraction "has its roots in the individual molecular motors working in every muscle cell -- the myosin molecule" ([@B68]). Myocardial contraction is mechanically manifested as the force and velocity generated during sarcomere shortening. It occurs when Ca^+2^ binds to troponin-C and reconfigures tropomyosin so that myosin heads fueled by the energy produced from ATP hydrolysis produce effective XB cycling.

The question of acceptability or usefulness of the term cardiac contractility should be based upon whether the word, contractility, can actually define a unique physiological process that is quantifiable. A multitude of methods have evolved for quantifying myocardial contractility, all of which are dependent upon the ability of sarcomeres to develop force and velocity ([@B140]; [@B82]; [@B119]; [@B64]). Myocardial contractility should be defined as the load and length-independent, intrinsic, kinetically controlled, chemo-mechanical processes responsible for the development of force (inotropy) and velocity (clinotropy).
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